Table 3.
The prognostic role of HIF-1α expression based on sample collection.
| Sample collection | HR with 95% CI | Heterogeneity (p) | p value | Studies | Cases | TSA |
|---|---|---|---|---|---|---|
| OS | ||||||
| Samples without previously received therapy | 1.70 (1.31–2.20) | 0.003 | <0.001 | 9 | 1447 | No need |
| Samples with previously received therapy | 0.69 (0.18–2.73) | 0.003 | 0.602 | 2 | 190 | More studies |
| DFS | ||||||
| Samples without previously received therapy | 1.47 (1.22–1.76) | 0.645 | <0.001 | 3 | 415 | More studies |
| Samples with previously received therapy | NA | NA | NA | NA | NA | NA |
95% CI, 95% confidence interval; DFS, disease-free survival; HIF-1α, hypoxia inducible factor-1α; HR, hazard ratio; NA, not applicable; OS, overall survival; TSA, trial sequential analysis.